Frank D. Lee
Frank D. Lee's purchase track record
Frank D. Lee has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2024 | PCRX | $100K | +42.4% | +112.4% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Transaction History
| BHC | ▲ Buy | Grant | 45,871 | $0 | 5/22/2026 | View on chart |
| BHC | ▼ Sell | Open Market | 24,456 | $133K | 5/19/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 261,818 | $0 | 2/11/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 41,488 | $852K | 1/30/2026 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 9,272 | $227K | 1/2/2026 | View on chart |
| BHC | ▼ Sell | Open Market | 15,912 | $122K | 8/21/2025 | View on chart |
| BHC | ▲ Buy | Grant | 54,347 | $0 | 5/16/2025 | View on chart |
| PCRX | ▲ Buy | Grant | 350,000 | $0 | 2/1/2025 | View on chart |
| PCRX | ▼ Sell | Tax Withholding | 9,375 | $172K | 1/2/2025 | View on chart |
| PCRX | ▲ Buy | Open Market | 8,264 | $100K | 8/12/2024 | View on chart |
| BHC | ▲ Buy | Grant | 35,360 | $0 | 5/17/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 99,520 | $0 | 1/2/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance
Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.